Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(18):1348-1349; doi:10.1093/jnci/djh282
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Bermejo, C.
Right arrow Articles by Thompson, I. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bermejo, C.
Right arrow Articles by Thompson, I. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

EDITORIAL

Localized Prostate Cancer: Quality of Life Meets Whitmore's Legacy

Carlos Bermejo, Alan R. Kristal, Steven B. Zeliadt, Scott Ramsey, Ian M. Thompson

Affiliations of authors: Division of Urology, University of Texas Health Science Center, San Antonio (CB, IMT); Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (ARK, SBZ, SR)

Correspondence to: Ian M. Thompson, MD, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229 (e-mail: thompsoni@uthscsa.edu)

The first 10% of the full text of this article appears below.

Dr. Willet Whitmore, the father of urologic oncology, is perhaps best remembered for his question: "For a patient with prostate cancer, if treatment for cure is necessary, is it possible? If possible, is it necessary?" This question crystallized the dilemma of decision making for patients and physicians and, in the third decade of prostate-specific antigen (PSA) screening, is now even more pertinent and pressing than ever. In this issue, Potosky et al. (1) contribute to . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?